4D Molecular Therapeutics, Inc. Common Stock (FDMT)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
4D Molecular Therapeutics, Inc. Common Stock (FDMT) is listed on Nasdaq, where it has traded since December 11, 2020.
- Listed On
- Nasdaq
- Listed Since
- December 11, 2020
- Employees
- 196
- Market Cap
- $597M
About 4D Molecular Therapeutics, Inc. Common Stock
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 153 institutions reported holding FDMT, with 58.0 million shares worth $771.2 million in aggregate. The largest reported holder was Janus Henderson (Jupiter Topco), with 5.7 million shares worth $76.5 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Janus Henderson (Jupiter Topco) | 5,746,289 | $76M | Added 9.51% |
| RA Capital Management | 5,049,779 | $67M | Unchanged |
| BlackRock | 4,546,059 | $60M | Added 9.67% |
| Goldman Sachs | 4,258,668 | $57M | Added 1.27% |
| Novo Holdings a/S | 3,249,178 | $43M | Reduced 11% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is FDMT?
4D Molecular Therapeutics, Inc. Common Stock (FDMT) is listed on Nasdaq, where it has traded since December 11, 2020.
Who are the largest institutional holders of FDMT?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of FDMT were Janus Henderson (Jupiter Topco), RA Capital Management and BlackRock.
How many institutions own FDMT?
153 institutions reported a position in FDMT for the quarter ended June 30, 2026, worth $771.2 million in total.
Did institutions buy or sell FDMT last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for FDMT.
Every reported institutional holder, plus insider and congressional trades in FDMT, on SentiSense.